A Translational Companion Protocol to GOG229O: A Randomized Phase II Study With a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer

Trial Profile

A Translational Companion Protocol to GOG229O: A Randomized Phase II Study With a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Trametinib (Primary) ; Uprosertib (Primary)
  • Indications Adenocarcinoma; Endometrial cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 13 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Aug 2014 Planned primary completion date changed from 1 Sep 2019 to 1 Aug 2019 as reported by ClinicalTrials.gov record.
    • 14 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top